REG - ReNeuron Group plc - Notice of Results

ReNeuronAnnouncement

18/11/2021 07:05

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211118:nRSR7497Sa&default-theme=true

RNS Number : 7497S  ReNeuron Group plc  18 November 2021

ReNeuron Group plc

("ReNeuron" or the "Company")

 

Notice of Results

Investor presentation

 

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of
cell-based therapeutics, will announce its interim results for the six months
ended 30 September 2021 and business update on Tuesday 30 November 2021.

 

Analyst briefing

Olav Hellebø, Chief Executive Officer, Catherine Isted, Chief Financial
Officer and Dr Stefano Pluchino, Chief Scientific Officer will be hosting a
briefing for analysts which will take place in the City of London on Tuesday
30 November 2021 at 13.00 (GMT) / 08:00 EST. A live webcast of the
presentation will also be available for those unable to attend the meeting
in-person.

 

For more information and to register to attend the meeting in-person or
require the link to the live webcast, please email reneuron@walbrookpr.com
(mailto:reneuron@walbrookpr.com) or call +44 (0)20 7933 8785.

 

Investor Briefing

Management will be hosting a live online presentation relating to the interim
results via the Investor Meet Company platform at 15.00 (GMT) on Tuesday 30
November. The presentation is open to all existing and potential shareholders.

 

Investors can sign up to Investor Meet Company for free and register for the
presentation here:
https://www.investormeetcompany.com/reneuron-group-plc/register-investor
(https://www.investormeetcompany.com/reneuron-group-plc/register-investor)

 

Investors who already follow ReNeuron on the Investor Meet Company platform
will automatically be invited.

 

Questions can be submitted pre-event via your IMC dashboard or in real time
during the presentation, via the "Ask a Question" function.  Whilst the
Company may not be in a position to answer every question it receives, it will
address the most prominent within the confines of information already
disclosed to the market through regulatory notifications. A recording of the
presentation, a PDF of the slides used, and responses to the Q&A session
will be available on the Investor Meet Company platform afterwards.

 

 

 
ENDS

 

Contacts:

 

 ReNeuron                                                 www.reneuron.com/investors (http://www.reneuron.com/investors)
 Olav Hellebø, Chief Executive Officer                    Via Walbrook PR

 Catherine Isted, Chief Financial Officer

 Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)  +44 (0)20 7710 7600

 Ben Maddison, Stewart Wallace

 Allenby Capital Limited (Joint Broker)                   +44 (0)20 3328 5656
 James Reeve/George Payne (Corporate Finance)
 Stefano Aquilino (Sales & Corporate Broking)

 Walbrook PR (Media & Investor Relations)                 +44 (0)20 7933 8780 or reneuron@walbrookpr.com
 Paul McManus, Alice Woodings                             +44 (0)7980 541 893 / +44 (0)7407 804 654

 

About ReNeuron

 

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique
stem cell technologies to develop 'off the shelf' stem cell treatments,
without the need for immunosuppressive drugs. The Company's lead cell therapy
candidate is in clinical development for the blindness-causing disease,
retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a
potential delivery system for drugs that treat diseases of the brain.  The
Company also has the ability through its conditionally immortalised induced
pluripotent stem cell (iPSC) platform to make any tissue cells of choice;
in-house programmes are focused on treatments for blood cancers and diabetes.

ReNeuron's shares are traded on the London AIM market under the symbol
RENE.L.  For further information visit www.reneuron.com
(http://www.reneuron.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORKDLFFFFLZFBL